Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex presented long-term Phase 2 data for barzolvolimab at the EAACI Annual Meeting, showing that up to 64% of patients with angioedema remained symptom-free seven months after stopping treatment. The results demonstrate durable off-treatment benefits, supporting the drug's potential to shift CSU treatment from symptom control to disease modification.
Key figures
- Drug Name
- barzolvolimab
- Phase Of Trial
- Phase 2
- Phase3 sites
- 500
- Phase3 countries
- 43
- Phase3 enrollment
- 1939
- Angioedema free rate week76
- 64%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.